Symbols / XTLB $2.43 -0.82% XTL Biopharmaceuticals Ltd.
XTLB Chart
About
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel. Its lead drug candidate is hCDR1, which is a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. The company has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 5.75M |
| Enterprise Value | 2.14B | Income | -6.31M | Sales | 968.00K |
| Book/sh | -0.00 | Cash/sh | 259000.00 | Dividend Yield | — |
| Payout | 0.00% | Employees | 10 | IPO | — |
| P/E | — | Forward P/E | — | PEG | — |
| P/S | 5.94 | P/B | — | P/C | — |
| EV/EBITDA | — | EV/Sales | 2212.39 | Quick Ratio | 0.46 |
| Current Ratio | 0.70 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -3.60 | EPS next Y | — | EPS Growth | — |
| Revenue Growth | — | Earnings | 2016-06-01 08:00 | ROA | -240.56% |
| ROE | -5.77% | ROIC | — | Gross Margin | -232.85% |
| Oper. Margin | -8.54% | Profit Margin | 0.00% | Shs Outstand | 2.37M |
| Shs Float | 274.56M | Short Float | 5.67% | Short Ratio | 1.13 |
| Short Interest | — | 52W High | 10.28 | 52W Low | 2.12 |
| Beta | 0.68 | Avg Volume | 179.69K | Volume | 12.43K |
| Target Price | — | Recom | None | Prev Close | $2.45 |
| Price | $2.43 | Change | -0.82% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$2.43
Latest analyst target
3. DCF / Fair value
—
Simplified FCF or EPS-based estimate
Ratings
Current target
$2.43
Low
—
High
—
Mean
—
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2015-05-08 | init | HC Wainwright & Co. | — → Buy | $6 |
- XTL investors will see every 4 ADSs become 1 on March 25 - Stock Titan Fri, 20 Mar 2026 07
- XTL Biopharmaceuticals Ltd. Receives Nasdaq Non-Compliance Notification Regarding Stockholders' Equity Requirements | XTLB Stock News - Quiver Quantitative Fri, 23 Jan 2026 08
- XTL Biopharmaceuticals Ends Acquisition Talks After NeuroNOS LOI Expires - TipRanks ue, 10 Mar 2026 07
- XTL Biopharmaceuticals Ltd. Sponsored ADR Trade Ideas — SWB:HHB0 - tradingview.com Wed, 01 Apr 2026 05
- XTL Update on Recent Developments - finance.yahoo.com hu, 29 Jan 2026 08
- XTL Biopharmaceuticals schedules extraordinary general meeting for February - Investing.com ue, 13 Jan 2026 08
- Nasdaq flags small drugmaker after shares trade under $1 - Stock Titan Wed, 24 Dec 2025 08
- XAIR Stock More Than Doubled Today — What’s Driving The Rally? - Stocktwits ue, 13 Jan 2026 08
- XTL Biopharmaceuticals Limited Faces Nasdaq Delisting Following Insolvency of Subsidiary The Social Proxy - Quiver Quantitative Fri, 27 Feb 2026 08
- Two Nobel winners back new autism drug push with XTL NeuroNOS deal - Stock Titan ue, 13 Jan 2026 08
- XTL Biopharmaceuticals stock falls on Nasdaq delisting notice - Investing.com Fri, 27 Feb 2026 08
- XTL Biopharmaceuticals Acquires 85% of NeuroNOS to Advance Autism Therapeutics with Leading Scientific Team - Quiver Quantitative ue, 13 Jan 2026 08
- XTL Biopharmaceuticals (NASDAQ: XTLB) sets one-for-four reverse ADS ratio change - Stock Titan Fri, 20 Mar 2026 07
- XTL Biopharmaceuticals plans 1-for-4 reverse ADS split By Investing.com - Investing.com Australia Sat, 21 Mar 2026 07
- XTL Biopharmaceuticals (XTLB) director discloses options on 1,000,000 shares - Stock Titan Mon, 23 Mar 2026 07
Insider Transactions
No recent insider transactions.
Financials
Statement View
| Line Item | Trend | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.45
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.45
|
0.00
|
0.00
|
0.00
|
| Cost Of Revenue |
|
0.45
|
0.00
|
0.00
|
—
|
| Reconciled Cost Of Revenue |
|
0.28
|
0.00
|
0.00
|
—
|
| Gross Profit |
|
0.00
|
0.00
|
0.00
|
—
|
| Operating Expense |
|
2.17
+184.31%
|
0.77
-13.07%
|
0.88
-14.65%
|
1.03
|
| Research And Development |
|
0.10
+216.13%
|
0.03
+3.33%
|
0.03
+0.00%
|
0.03
|
| Selling General And Administration |
|
2.05
+178.75%
|
0.73
-13.65%
|
0.85
-15.08%
|
1.00
|
| Selling And Marketing Expense |
|
0.18
|
0.00
|
0.00
|
—
|
| General And Administrative Expense |
|
1.87
+154.50%
|
0.73
-13.65%
|
0.85
-15.08%
|
1.00
|
| Salaries And Wages |
|
0.84
+396.47%
|
0.17
-14.57%
|
0.20
+97.03%
|
0.10
|
| Other Gand A |
|
0.90
+107.16%
|
0.43
-2.26%
|
0.44
-32.47%
|
0.66
|
| Total Expenses |
|
2.62
+242.88%
|
0.77
-13.07%
|
0.88
-14.65%
|
1.03
|
| Operating Income |
|
-2.17
-183.92%
|
-0.77
+13.07%
|
-0.88
+14.65%
|
-1.03
|
| Total Operating Income As Reported |
|
-2.17
-183.92%
|
-0.77
+13.07%
|
-0.88
+14.65%
|
-1.03
|
| EBITDA |
|
-0.93
+47.81%
|
-1.78
-32.29%
|
-1.35
-30.78%
|
-1.03
|
| Normalized EBITDA |
|
-2.00
-174.31%
|
-0.73
+14.75%
|
-0.85
+65.96%
|
-2.51
|
| Reconciled Depreciation |
|
0.20
|
0.00
-100.00%
|
0.00
+0.00%
|
0.00
|
| EBIT |
|
-1.13
+36.64%
|
-1.78
-32.20%
|
-1.35
-30.75%
|
-1.03
|
| Total Unusual Items |
|
1.07
+201.23%
|
-1.05
-113.79%
|
-0.49
-133.33%
|
1.48
|
| Total Unusual Items Excluding Goodwill |
|
1.07
+201.23%
|
-1.05
-113.79%
|
-0.49
-133.33%
|
1.48
|
| Net Income |
|
-1.03
+42.37%
|
-1.78
-32.20%
|
-1.35
-409.89%
|
0.43
|
| Pretax Income |
|
-1.16
+35.07%
|
-1.78
-32.20%
|
-1.35
-409.89%
|
0.43
|
| Net Non Operating Interest Income Expense |
|
-0.05
-240.54%
|
0.04
+48.00%
|
0.03
+292.31%
|
-0.01
|
| Interest Expense Non Operating |
|
0.03
|
0.00
|
0.00
|
—
|
| Net Interest Income |
|
-0.05
-240.54%
|
0.04
+48.00%
|
0.03
+292.31%
|
-0.01
|
| Interest Expense |
|
0.03
|
0.00
|
0.00
|
—
|
| Interest Income Non Operating |
|
0.03
-17.07%
|
0.04
+13.89%
|
0.04
+350.00%
|
0.01
|
| Interest Income |
|
0.03
-17.07%
|
0.04
+13.89%
|
0.04
+350.00%
|
0.01
|
| Other Income Expense |
|
1.07
+201.23%
|
-1.05
-113.79%
|
-0.49
-133.33%
|
1.48
|
| Gain On Sale Of Security |
|
1.07
+201.23%
|
-1.05
-113.79%
|
-0.49
-133.33%
|
1.48
|
| Tax Provision |
|
-0.13
|
0.00
|
0.00
|
—
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
-100.00%
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.12
|
0.00
|
0.00
-100.00%
|
0.34
|
| Net Income Including Noncontrolling Interests |
|
-1.03
+42.37%
|
-1.78
-32.20%
|
-1.35
-409.89%
|
0.43
|
| Net Income From Continuing Operation Net Minority Interest |
|
-1.03
+42.37%
|
-1.78
-32.20%
|
-1.35
-409.89%
|
0.43
|
| Net Income From Continuing And Discontinued Operation |
|
-1.03
+42.37%
|
-1.78
-32.20%
|
-1.35
-409.89%
|
0.43
|
| Net Income Continuous Operations |
|
-1.03
+42.37%
|
-1.78
-32.20%
|
-1.35
-409.89%
|
0.43
|
| Normalized Income |
|
-1.97
-171.17%
|
-0.73
+14.85%
|
-0.85
-21.48%
|
-0.70
|
| Net Income Common Stockholders |
|
-1.03
+42.37%
|
-1.78
-32.20%
|
-1.35
-409.89%
|
0.43
|
| Diluted EPS |
|
-0.30
+0.00%
|
-0.30
-50.00%
|
-0.20
-447.15%
|
-0.04
|
| Basic EPS |
|
-0.20
+33.33%
|
-0.30
-50.00%
|
-0.20
-300.00%
|
0.10
|
| Basic Average Shares |
|
6.73
+23.52%
|
5.45
+0.00%
|
5.45
+2.43%
|
5.32
|
| Diluted Average Shares |
|
7.04
+29.23%
|
5.45
0.00%
|
5.45
-11.48%
|
6.16
|
| Diluted NI Availto Com Stockholders |
|
-1.03
+42.37%
|
-1.78
-32.20%
|
-1.35
-499.11%
|
-0.23
|
| Average Dilution Earnings |
|
—
|
0.00
|
0.00
+100.00%
|
-0.66
|
| Amortization |
|
0.03
|
0.00
|
0.00
|
—
|
| Amortization Of Intangibles Income Statement |
|
0.03
|
0.00
|
0.00
|
—
|
| Depreciation Amortization Depletion Income Statement |
|
0.03
|
0.00
|
0.00
|
—
|
| Depreciation And Amortization In Income Statement |
|
0.03
|
0.00
|
0.00
|
—
|
| Insurance And Claims |
|
0.10
-15.97%
|
0.12
-41.09%
|
0.20
-11.79%
|
0.23
|
| Rent And Landing Fees |
|
0.03
+125.00%
|
0.01
+100.00%
|
0.01
-60.00%
|
0.01
|
| Rent Expense Supplemental |
|
0.03
+125.00%
|
0.01
+100.00%
|
0.01
-60.00%
|
0.01
|
| Total Other Finance Cost |
|
0.06
+1350.00%
|
0.00
-63.64%
|
0.01
-47.62%
|
0.02
|
| Line Item | Trend | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
8.55
+252.43%
|
2.43
-42.04%
|
4.19
-36.75%
|
6.62
|
| Current Assets |
|
1.34
-34.51%
|
2.05
-46.24%
|
3.81
-38.98%
|
6.24
|
| Cash Cash Equivalents And Short Term Investments |
|
1.14
-43.02%
|
2.01
-46.09%
|
3.72
-39.27%
|
6.13
|
| Cash And Cash Equivalents |
|
0.37
-73.52%
|
1.40
-33.09%
|
2.09
-29.47%
|
2.97
|
| Cash Equivalents |
|
0.00
-100.00%
|
1.27
+86.20%
|
0.68
-71.27%
|
2.37
|
| Cash Financial |
|
0.37
+178.95%
|
0.13
-90.59%
|
1.41
+135.89%
|
0.60
|
| Other Short Term Investments |
|
0.77
+27.60%
|
0.60
-62.81%
|
1.63
-48.48%
|
3.16
|
| Receivables |
|
0.15
+417.24%
|
0.03
-59.15%
|
0.07
-24.47%
|
0.09
|
| Accounts Receivable |
|
0.10
|
0.00
|
—
|
—
|
| Gross Accounts Receivable |
|
0.14
|
0.00
|
—
|
—
|
| Allowance For Doubtful Accounts Receivable |
|
-0.04
|
0.00
|
—
|
—
|
| Other Receivables |
|
0.05
+75.86%
|
0.03
-59.15%
|
0.07
-24.47%
|
0.09
|
| Prepaid Assets |
|
0.05
+75.86%
|
0.03
-59.15%
|
0.07
-24.47%
|
0.09
|
| Other Current Assets |
|
0.05
+327.27%
|
0.01
-21.43%
|
0.01
-12.50%
|
0.02
|
| Total Non Current Assets |
|
7.21
+1797.37%
|
0.38
+0.00%
|
0.38
-0.26%
|
0.38
|
| Net PPE |
|
0.19
|
0.00
|
0.00
-100.00%
|
0.00
|
| Goodwill And Other Intangible Assets |
|
7.01
+1744.47%
|
0.38
+0.00%
|
0.38
+0.00%
|
0.38
|
| Goodwill |
|
3.19
|
0.00
|
—
|
—
|
| Other Intangible Assets |
|
3.82
+904.21%
|
0.38
+0.00%
|
0.38
+0.00%
|
0.38
|
| Investments And Advances |
|
0.01
|
0.00
|
—
|
—
|
| Total Liabilities Net Minority Interest |
|
3.12
+1412.14%
|
0.21
+10.16%
|
0.19
-85.45%
|
1.28
|
| Current Liabilities |
|
2.21
+971.36%
|
0.21
+10.16%
|
0.19
-19.05%
|
0.23
|
| Payables And Accrued Expenses |
|
0.72
+249.03%
|
0.21
+10.16%
|
0.19
-19.05%
|
0.23
|
| Payables |
|
0.23
+22600.00%
|
0.00
-50.00%
|
0.00
+0.00%
|
0.00
|
| Accounts Payable |
|
0.20
+19500.00%
|
0.00
-50.00%
|
0.00
+0.00%
|
0.00
|
| Other Payable |
|
0.03
|
—
|
—
|
—
|
| Current Accrued Expenses |
|
0.49
+140.00%
|
0.20
+10.81%
|
0.18
-19.21%
|
0.23
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
0.05
|
0.00
|
—
|
—
|
| Current Debt And Capital Lease Obligation |
|
0.14
|
—
|
—
|
—
|
| Current Debt |
|
0.14
|
—
|
—
|
—
|
| Current Deferred Liabilities |
|
0.02
|
0.00
|
—
|
—
|
| Current Deferred Revenue |
|
0.02
|
0.00
|
—
|
—
|
| Other Current Liabilities |
|
1.28
|
—
|
—
|
—
|
| Total Non Current Liabilities Net Minority Interest |
|
0.91
|
0.00
|
0.00
-100.00%
|
1.05
|
| Non Current Deferred Liabilities |
|
0.22
|
0.00
|
—
|
—
|
| Non Current Deferred Taxes Liabilities |
|
0.22
|
0.00
|
—
|
—
|
| Stockholders Equity |
|
5.43
+144.82%
|
2.22
-44.49%
|
4.00
-25.01%
|
5.33
|
| Common Stock Equity |
|
5.43
+144.82%
|
2.22
-44.49%
|
4.00
-25.01%
|
5.33
|
| Capital Stock |
|
23.14
+63.87%
|
14.12
+0.00%
|
14.12
+0.00%
|
14.12
|
| Common Stock |
|
23.14
+63.87%
|
14.12
+0.00%
|
14.12
+0.00%
|
14.12
|
| Share Issued |
|
881.39
+61.75%
|
544.91
+0.00%
|
544.91
+0.00%
|
544.91
|
| Ordinary Shares Number |
|
881.39
+61.75%
|
544.91
+0.00%
|
544.91
+0.00%
|
544.91
|
| Additional Paid In Capital |
|
141.29
-3.44%
|
146.33
+0.00%
|
146.33
+0.00%
|
146.33
|
| Retained Earnings |
|
-159.01
-0.48%
|
-158.25
-1.14%
|
-156.47
-0.86%
|
-155.13
|
| Gains Losses Not Affecting Retained Earnings |
|
0.02
+0.00%
|
0.02
+0.00%
|
0.02
+0.00%
|
0.02
|
| Other Equity Adjustments |
|
0.02
+0.00%
|
0.02
+0.00%
|
0.02
+0.00%
|
0.02
|
| Total Equity Gross Minority Interest |
|
5.43
+144.82%
|
2.22
-44.49%
|
4.00
-25.01%
|
5.33
|
| Total Capitalization |
|
5.43
+144.82%
|
2.22
-44.49%
|
4.00
-25.01%
|
5.33
|
| Working Capital |
|
-0.87
-147.12%
|
1.84
-49.16%
|
3.62
-39.74%
|
6.01
|
| Invested Capital |
|
5.57
+151.04%
|
2.22
-44.49%
|
4.00
-25.01%
|
5.33
|
| Total Debt |
|
0.14
|
—
|
—
|
—
|
| Net Tangible Assets |
|
-1.57
-185.54%
|
1.84
-49.16%
|
3.62
-26.93%
|
4.95
|
| Tangible Book Value |
|
-1.57
-185.54%
|
1.84
-49.16%
|
3.62
-26.93%
|
4.95
|
| Available For Sale Securities |
|
0.01
|
—
|
—
|
—
|
| Derivative Product Liabilities |
|
0.69
|
0.00
|
0.00
-100.00%
|
1.05
|
| Investmentin Financial Assets |
|
0.01
|
0.00
|
—
|
—
|
| Line Of Credit |
|
0.14
|
0.00
|
—
|
—
|
| Line Item | Trend | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-1.62
-128.85%
|
-0.71
+21.53%
|
-0.90
+14.11%
|
-1.05
|
| Cash Flow From Continuing Operating Activities |
|
-1.62
-128.85%
|
-0.71
+21.53%
|
-0.90
+14.11%
|
-1.05
|
| Net Income From Continuing Operations |
|
-1.03
+42.37%
|
-1.78
-32.20%
|
-1.35
-409.89%
|
0.43
|
| Depreciation Amortization Depletion |
|
0.20
|
0.00
-100.00%
|
0.00
+0.00%
|
0.00
|
| Depreciation |
|
—
|
0.00
-100.00%
|
0.00
+0.00%
|
0.00
|
| Depreciation And Amortization |
|
0.20
|
0.00
-100.00%
|
0.00
+0.00%
|
0.00
|
| Other Non Cash Items |
|
-0.02
-42.86%
|
-0.01
+46.15%
|
-0.03
-225.00%
|
-0.01
|
| Stock Based Compensation |
|
0.26
+8700.00%
|
0.00
-78.57%
|
0.01
-62.16%
|
0.04
|
| Deferred Tax |
|
-0.13
|
0.00
|
0.00
|
—
|
| Deferred Income Tax |
|
-0.13
|
0.00
|
0.00
|
—
|
| Operating Gains Losses |
|
-0.93
-3529.63%
|
0.03
+102.56%
|
-1.05
-47.83%
|
-0.71
|
| Gain Loss On Investment Securities |
|
-0.93
|
—
|
-1.05
-46.59%
|
-0.72
|
| Unrealized Gain Loss On Investment Securities |
|
-0.17
-116.34%
|
1.02
-33.25%
|
1.53
+304.95%
|
-0.75
|
| Net Foreign Currency Exchange Gain Loss |
|
—
|
0.03
+170.00%
|
0.01
+66.67%
|
0.01
|
| Change In Working Capital |
|
0.19
+195.31%
|
0.06
+436.84%
|
-0.02
+64.81%
|
-0.05
|
| Change In Receivables |
|
0.04
|
0.00
|
0.00
|
—
|
| Changes In Account Receivables |
|
0.04
|
0.00
|
0.00
|
—
|
| Change In Prepaid Assets |
|
-0.06
-228.89%
|
0.04
+80.00%
|
0.03
+180.65%
|
-0.03
|
| Change In Payables And Accrued Expense |
|
0.21
+994.74%
|
0.02
+143.18%
|
-0.04
-91.30%
|
-0.02
|
| Change In Payable |
|
0.21
+994.74%
|
0.02
+143.18%
|
-0.04
-91.30%
|
-0.02
|
| Change In Account Payable |
|
0.21
+994.74%
|
0.02
+143.18%
|
-0.04
-91.30%
|
-0.02
|
| Investing Cash Flow |
|
-0.84
-2158.54%
|
0.04
+13.89%
|
0.04
+350.00%
|
0.01
|
| Cash Flow From Continuing Investing Activities |
|
-0.84
-2158.54%
|
0.04
+13.89%
|
0.04
+350.00%
|
0.01
|
| Net PPE Purchase And Sale |
|
-0.05
|
0.00
|
0.00
|
0.00
|
| Purchase Of PPE |
|
-0.05
|
0.00
|
0.00
|
0.00
|
| Capital Expenditure |
|
-0.05
|
—
|
—
|
—
|
| Net Investment Purchase And Sale |
|
-0.01
|
0.00
|
0.00
|
0.00
|
| Purchase Of Investment |
|
-0.01
|
0.00
|
0.00
|
—
|
| Sale Of Investment |
|
—
|
—
|
—
|
0.00
|
| Net Business Purchase And Sale |
|
-0.41
|
0.00
|
0.00
|
—
|
| Purchase Of Business |
|
-0.41
|
0.00
|
0.00
|
—
|
| Net Other Investing Changes |
|
-0.40
|
—
|
—
|
—
|
| Financing Cash Flow |
|
1.45
|
0.00
|
0.00
-100.00%
|
0.39
|
| Cash Flow From Continuing Financing Activities |
|
1.45
|
0.00
|
0.00
-100.00%
|
0.39
|
| Net Issuance Payments Of Debt |
|
-0.01
|
0.00
|
0.00
|
—
|
| Repayment Of Debt |
|
-0.01
|
0.00
|
0.00
|
—
|
| Short Term Debt Payments |
|
-0.01
|
0.00
|
0.00
|
—
|
| Net Short Term Debt Issuance |
|
-0.01
|
0.00
|
0.00
|
—
|
| Net Common Stock Issuance |
|
1.46
|
0.00
|
0.00
|
—
|
| Proceeds From Stock Option Exercised |
|
—
|
0.00
|
0.00
-100.00%
|
0.39
|
| Changes In Cash |
|
-1.01
-52.40%
|
-0.67
+23.01%
|
-0.86
-31.86%
|
-0.66
|
| Effect Of Exchange Rate Changes |
|
-0.01
+44.44%
|
-0.03
-170.00%
|
-0.01
-66.67%
|
-0.01
|
| Beginning Cash Position |
|
1.40
-33.09%
|
2.09
-29.47%
|
2.97
-18.23%
|
3.63
|
| End Cash Position |
|
0.37
-73.52%
|
1.40
-33.09%
|
2.09
-29.47%
|
2.97
|
| Free Cash Flow |
|
-1.67
-136.49%
|
-0.71
+21.53%
|
-0.90
+14.11%
|
-1.05
|
| Common Stock Issuance |
|
1.46
|
0.00
|
0.00
|
—
|
| Interest Received CFI |
|
0.03
-17.07%
|
0.04
+13.89%
|
0.04
+350.00%
|
0.01
|
| Issuance Of Capital Stock |
|
1.46
|
0.00
|
0.00
|
—
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 42008-12-03 View
- 42008-11-04 View
- 42008-11-04 View
- 42008-06-19 View
- 42008-06-11 View
- 42008-06-06 View
- 42008-05-06 View
- 42008-05-02 View
- 42008-04-16 View
- 42008-04-04 View
- 42008-04-02 View
- 42008-03-20 View
- 42008-03-19 View
- 42008-03-19 View
- 42008-03-10 View
- 42008-02-29 View
- 42008-02-28 View
- 42008-02-28 View
- 42008-02-22 View
- 42008-02-19 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|